JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

Search

Dynavax Technologies Corp

Abrir

SetorSaúde

10.36 -1.05

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.31

Máximo

10.57

Indicadores-chave

By Trading Economics

Rendimento

115M

19M

Vendas

27M

95M

P/E

Médio do Setor

58.75

37.461

Margem de lucro

19.615

Funcionários

405

EBITDA

119M

25M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+116.73% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-108M

1.2B

Abertura anterior

11.41

Fecho anterior

10.36

Sentimento de Notícias

By Acuity

47%

53%

149 / 373 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Dynavax Technologies Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de out. de 2025, 23:50 UTC

Ações em Alta

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 de out. de 2025, 23:25 UTC

Ganhos

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 de out. de 2025, 23:18 UTC

Ganhos

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 de out. de 2025, 22:20 UTC

Ganhos

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 de out. de 2025, 22:13 UTC

Ganhos

Wal-Mart de Mexico Net Profit Falls in 3Q

28 de out. de 2025, 21:38 UTC

Ganhos

Correction to Visa Sales Jump Article

28 de out. de 2025, 21:17 UTC

Ganhos

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 de out. de 2025, 21:07 UTC

Ganhos

Visa Sales Jump as Consumers Keep Spending -- Update

28 de out. de 2025, 21:02 UTC

Ganhos

Mondelez Tempers Outlook as Costs Rise

28 de out. de 2025, 23:51 UTC

Conversa de Mercado

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 de out. de 2025, 23:42 UTC

Conversa de Mercado

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 de out. de 2025, 23:02 UTC

Ganhos

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 de out. de 2025, 23:01 UTC

Ganhos

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 de out. de 2025, 22:46 UTC

Ganhos

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 de out. de 2025, 22:45 UTC

Ganhos

SK Hynix 3Q Net KRW12.6T >000660.SE

28 de out. de 2025, 22:44 UTC

Ganhos

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 de out. de 2025, 22:43 UTC

Ganhos

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 de out. de 2025, 22:42 UTC

Ganhos

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 de out. de 2025, 22:40 UTC

Ganhos

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 de out. de 2025, 22:40 UTC

Ganhos

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 de out. de 2025, 22:20 UTC

Ganhos

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 de out. de 2025, 22:02 UTC

Ganhos

Review & Preview: Earnings Extravaganza -- Barrons.com

28 de out. de 2025, 21:42 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

28 de out. de 2025, 21:42 UTC

Conversa de Mercado
Ganhos

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 de out. de 2025, 21:20 UTC

Ganhos

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 de out. de 2025, 21:19 UTC

Ganhos

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 de out. de 2025, 21:18 UTC

Ganhos

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparação entre Pares

Variação de preço

Dynavax Technologies Corp Previsão

Preço-alvo

By TipRanks

116.73% parte superior

Previsão para 12 meses

Média 22.67 USD  116.73%

Máximo 32 USD

Mínimo 11 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Dynavax Technologies Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

3

Comprar

0

Manter

1

Vender

Pontuação Técnica

By Trading Central

9.62 / 10.9Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

149 / 373 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Dynavax Technologies Corp

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
help-icon Live chat